361 related articles for article (PubMed ID: 31995577)
21. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
Wang Y; Yang F; Shen Y; Zhang W; Wang J; Chang VT; Andersson BS; Qazilbash MH; Champlin RE; Berenson JR; Guan X; Wang ML
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26582244
[TBL] [Abstract][Full Text] [Related]
22. Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.
Molica S; Giannarelli D; Montserrat E
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):216-223. PubMed ID: 33199185
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
Jain N; O'Brien S
Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
[TBL] [Abstract][Full Text] [Related]
24. Highlights in the treatment of chronic lymphocytic leukemia from the 2014 meeting of the American Society of Hematology.
Molica S
Expert Rev Hematol; 2015 Jun; 8(3):277-81. PubMed ID: 25804936
[TBL] [Abstract][Full Text] [Related]
25. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
26. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
27. Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves.
Alrawashdh N; Persky DO; McBride A; Sweasy J; Erstad B; Abraham I
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e820-e831. PubMed ID: 34274291
[TBL] [Abstract][Full Text] [Related]
28. Obinutuzumab for chronic lymphocytic leukemia.
Rioufol C; Salles G
Expert Rev Hematol; 2014 Oct; 7(5):533-43. PubMed ID: 25163491
[TBL] [Abstract][Full Text] [Related]
29. Ofatumumab regimens in chronic lymphocytic leukemia: a meta-analysis.
Ashoub MH; Naseri A; Mohammadi P; Mohammadi M
Ann Hematol; 2023 Jun; 102(6):1301-1306. PubMed ID: 37138022
[TBL] [Abstract][Full Text] [Related]
30. A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia.
Städler N; Shang A; Bosch F; Briggs A; Goede V; Berthier A; Renaudin C; Leblond V
Adv Ther; 2016 Oct; 33(10):1814-1830. PubMed ID: 27535291
[TBL] [Abstract][Full Text] [Related]
31. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.
Dartigeas C; Van Den Neste E; Léger J; Maisonneuve H; Berthou C; Dilhuydy MS; De Guibert S; Leprêtre S; Béné MC; Nguyen-Khac F; Letestu R; Cymbalista F; Rodon P; Aurran-Schleinitz T; Vilque JP; Tournilhac O; Mahé B; Laribi K; Michallet AS; Delmer A; Feugier P; Lévy V; Delépine R; Colombat P; Leblond V; ;
Lancet Haematol; 2018 Feb; 5(2):e82-e94. PubMed ID: 29275118
[TBL] [Abstract][Full Text] [Related]
32. Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
Freise KJ; Jones AK; Menon RM; Verdugo ME; Humerickhouse RA; Awni WM; Salem AH
Hematol Oncol; 2017 Dec; 35(4):679-684. PubMed ID: 27982454
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Plus Anti-CD20 Antibody Therapy Compared With Chemoimmunotherapy as Front-line Treatment for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Nguyen TT; Thanh Nhu N; Tran VK; Van Cau N; Lin CF
J Immunother; 2023 Oct; 46(8):299-309. PubMed ID: 37216406
[TBL] [Abstract][Full Text] [Related]
34. Emerging immunological drugs for chronic lymphocytic leukemia.
Robak P; Smolewski P; Robak T
Expert Opin Emerg Drugs; 2015 Sep; 20(3):423-47. PubMed ID: 26153226
[TBL] [Abstract][Full Text] [Related]
35. The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission.
Muchtar E; Vidal L; Ram R; Gafter-Gvili A; Shpilberg O; Raanani P
Cochrane Database Syst Rev; 2013 Mar; (3):CD009594. PubMed ID: 23543579
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow up of the combination of ofatumumab, high-dose methylprednisolone, and lenalidomide for untreated chronic lymphocytic leukemia with biomarker analysis.
Chavez JC; Grajales A; Sandoval-Sus J; Turba E; Nodzon L; Uriepero-Palma A; Ammad-Ud-Din M; Sahakian E; Komrokji R; Sokol L; Locke FL; Shah B; Lancet J; Sotomayor EM; Kharfan-Dabaja MA; Bello C; Pinilla-Ibarz J
Clin Lymphoma Myeloma Leuk; 2024 Jun; 24(6):382-391.e2. PubMed ID: 38508880
[TBL] [Abstract][Full Text] [Related]
37. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.
van Oers MH; Kuliczkowski K; Smolej L; Petrini M; Offner F; Grosicki S; Levin MD; Gupta I; Phillips J; Williams V; Manson S; Lisby S; Geisler C;
Lancet Oncol; 2015 Oct; 16(13):1370-9. PubMed ID: 26377300
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.
Liang L; Zhao M; Zhu YC; Hu X; Yang LP; Liu H
Ann Hematol; 2016 Sep; 95(9):1473-82. PubMed ID: 27329288
[TBL] [Abstract][Full Text] [Related]
39. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
Shah A; Mangaonkar A
Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
[TBL] [Abstract][Full Text] [Related]
40. Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.
Korycka-Wołowiec A; Wołowiec D; Robak T
Expert Opin Drug Saf; 2015; 14(12):1945-59. PubMed ID: 26566719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
